Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) stock jumped 12.67% on Friday to $24.99 against a previous-day closing price of $22.18. With 0.66 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.38 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $25.34 whereas the lowest price it dropped to was $22.60. The 52-week range on ARCT shows that it touched its highest point at $37.75 and its lowest point at $14.21 during that stretch. It currently has a 1-year price target of $62.00. Beta for the stock currently stands at 2.56.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ARCT was up-trending over the past week, with a rise of 30.43%, but this was up by 21.31% over a month. Three-month performance dropped to -19.75% while six-month performance fell -6.51%. The stock gained 43.13% in the past year, while it has gained 47.35% so far this year. A look at the trailing 12-month EPS for ARCT yields 3.61 with Next year EPS estimates of -3.33. For the next quarter, that number is -0.95. This implies an EPS growth rate of -601.00% for this year and -89.74% for next year.
Float and Shares Shorts:
At present, 26.55 million ARCT shares are outstanding with a float of 24.31 million shares on hand for trading. On Oct 30, 2023, short shares totaled 4.99 million, which was 18.75% higher than short shares on Sep 28, 2023. In addition to Mr. Joseph E. Payne M.Sc. as the firm’s Founder, President, CEO & Director, Dr. Padmanabh Chivukula serves as its Founder, Chief Scientific Officer, COO & Secretary.
Institutional Ownership:
Through their ownership of 84.74% of ARCT’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 62.16% of ARCT, in contrast to 27.61% held by mutual funds. Shares owned by individuals account for 14.22%. As the largest shareholder in ARCT with 17.71% of the stake, Federated Global Investment Manag holds 4,711,512 shares worth 4,711,512. A second-largest stockholder of ARCT, ARK Investment Management LLC, holds 1,901,546 shares, controlling over 7.15% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in ARCT, holding 1,737,898 shares or 6.53% stake. With a 9.22% stake in ARCT, the Federated Hermes Kaufmann Fund is the largest stakeholder. A total of 2,451,016 shares are owned by the mutual fund manager. The Federated Hermes Kaufmann Small C, which owns about 8.26% of ARCT stock, is the second-largest Mutual Fund holder. It holds 2,198,020 shares valued at 41.98 million. ARK Genomic Revolution ETF holds 6.96% of the stake in ARCT, owning 1,852,356 shares worth 35.38 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ARCT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ARCT analysts setting a high price target of $140.00 and a low target of $18.00, the average target price over the next 12 months is $62.00. Based on these targets, ARCT could surge 460.22% to reach the target high and fall by -27.97% to reach the target low. Reaching the average price target will result in a growth of 148.1% from current levels.
Summary of Insider Activity:
Insiders traded ARCT stock several times over the past three months with 0 Buys and 2 Sells. In these transactions, 0 shares were bought while 10,000 shares were sold. The number of buy transactions has increased to 9 while that of sell transactions has risen to 13 over the past year. The total number of shares bought during that period was 22,381 while 103,936 shares were sold.
